Iain M. Cockburn is the Richard C. Shipley Professor in the Questrom School of Business at Boston University, where he teaches and performs research in the areas of business strategy, intellectual property, economics of innovation, and management of high tech companies.
Professor Cockburn graduated from the University of London in 1984, and completed his PhD in economics at Harvard University in 1990. Prior to joining the faculty of Boston University, he was the VanDusen Professor of Business Administration in the Faculty of Commerce at the University of British Columbia. He is a Research Associate at the National Bureau of Economic Research in Cambridge, Massachusetts.
Professor Cockburn is an authority on the economics of intellectual property. He has published numerous papers in leading academic journals in economics and management. Among his most highly cited articles are “Generics and New Goods in Pharmaceutical Price Indexes” in American Economic Review, “Scale, Scope, and Spillovers: Determinants of Research Productivity in the Pharmaceutical Industry” in RAND Journal of Economics, “Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery” in Journal of Industrial Economics, “Is the Pharmaceutical Industry in a Productivity Crisis” in Innovation Policy and the Economy, “The Market for Follow-on Biologics: How Will It Evolve?” in Health Affairs, “Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy” in Capitalism and Society, “Patents and the Global Diffusion of New Drugs” in American Economic Review, and “Deals Not Done: Sources of Failure in the Market for Ideas” in Strategic Management Journal.
Professor Cockburn has been a consultant on business strategy to variety of life sciences and technology companies, and on public policy to government agencies in the US, the UK, and Canada. He has provided expert testimony in numerous litigation and arbitration matters on issues such as licensing and collaboration agreements, patent damages, antitrust, class certification, brand-generic competition, Medicaid and Medicare reimbursement, off-label marketing, transfer pricing, and misappropriation of trade secrets.